Theravance Biopharma
TBPH
TBPH
112 hedge funds and large institutions have $567M invested in Theravance Biopharma in 2022 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 35 increasing their positions, 45 reducing their positions, and 15 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding in top 10
Funds holding in top 10: →
more ownership
Funds ownership: →
more call options, than puts
Call options by funds: $ | Put options by funds: $
less capital invested
Capital invested by funds: $ → $
7% less funds holding
Funds holding: 120 → 112 (-8)
22% less repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 45
40% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 15
Holders
112
Holding in Top 10
3
Calls
$1.28M
Puts
$1.24M
Top Buyers
| 1 | +$25.7M | |
| 2 | +$8.31M | |
| 3 | +$7.47M | |
| 4 |
NM
Newtyn Management
New York
|
+$6.01M |
| 5 |
D.E. Shaw & Co
New York
|
+$1.28M |
Top Sellers
| 1 | -$4.98M | |
| 2 | -$3.65M | |
| 3 | -$3.56M | |
| 4 |
Morgan Stanley
New York
|
-$2.5M |
| 5 |
BG
Baupost Group
Boston,
Massachusetts
|
-$2.03M |